BioSpace News Archive

Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier.

Wave Life Sciences Ltd. today announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9-ALS/FTD).

Life Biosciences announced the appointment of Ming Yang, Ph.D., as Senior Vice President of Research and Development.

T2 Biosystems, Inc. today announced financial results for the first quarter ended March 31, 2023.

EPIC BIO today announced Amber Salzman, chief executive officer, and Alexandra Collin de l’Hortet, Ph.D., head of therapeutics will participate in a Fireside Chat at the Stifel Genetic Medicines Day on Tuesday, May 30, 2023, at 1:15 p.m. ET.

electroCore, Inc. today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the 13th Annual LD Micro Invitational XIII in Los Angeles, California from June 6-8, 2023.

89bio, Inc. today announced the initiation of ENTRUST, a Phase 3 trial evaluating the efficacy, safety and tolerability of pegozafermin in patients with severe hypertriglyceridemia (SHTG).

Aadi Bioscience, Inc. announced today participation at the following investor events.

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company received IND (Investigational New Drug) approval from the Korean MFDS (Ministry of Food and Drug Safety) to initiate a Phase I clinical trial of PMC-403, the Company’s novel TIE2 agonistic antibody.

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June.